Novartis AG (NYSE:NVS; SIX:NOVN) is expanding, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is shrinking and Eli Lilly and Co. (NYSE:LLY) is somewhere in between. Over the last five years, Novartis' top line has grown at an average annual rate of 7%. The pharma has consistently spent about 16% of revenues on R&D, while